Pfizer Seeks New Production Approval in Michigan Trade Zone

You might care about this because Pfizer Inc. wants to expand its production activities in Michigan. Specifically, the company has asked the Foreign-Trade Zones Board for approval to produce a pharmaceutical intermediate product called phthalimido lactol within its facilities in Kalamazoo and Portage. These facilities are part of Foreign-Trade Zone 43. This approval would allow Pfizer to use certain foreign-status materials and components under special trade rules. The specific material they want to use is 3-phthalimidopropionaldehyde or 3-PPA. Both the finished product and the component have a duty rate of 6.5 percent. A key part of this request involves how these materials are treated at the border. The foreign component 3-PPA is subject to duties under either Section 232 or Section 301 of US trade laws. Because of these specific duties, the material must enter the Foreign-Trade Zone in what is called privileged foreign status. This status means the material's duty rate is set at the time it enters the zone, and it remains fixed even if it is changed or manufactured into another product within the zone. This can offer benefits for companies operating within these zones. The public has until August 31 2026 to submit comments on this proposal to the FTZ Board. This notification provides details on Pfizer's request and the process for public input. This request is particularly interesting for several reasons. First, it highlights how companies use Foreign-Trade Zones to manage their costs and operations. FTZs allow businesses to defer or reduce customs duties on foreign merchandise until it leaves the zone for US consumption. If the merchandise is exported from the zone, no US duties are paid at all. For pharmaceutical manufacturing, where supply chains can be complex and involve global sourcing, these benefits can be substantial. Second, the requirement for materials to be admitted in privileged foreign status makes this proposal noteworthy. This status is triggered because the foreign-status material 3-PPA is subject to duties imposed under Section 232 or Section 301 of US trade law. These sections deal with national security and unfair trade practices respectively. When a material is in privileged foreign status its tariff classification and duty rate are fixed at the time it enters the zone. This means any manufacturing or changes made to the material inside the zone will not alter its original duty rate when it eventually enters the US market. This provides certainty and potentially different duty treatment compared to non-privileged foreign status where the duty might be assessed on the finished product at the time it leaves the zone. This specific status choice reflects a strategic decision by Pfizer to navigate trade regulations for its pharmaceutical production. Several groups would find this legal document highly relevant. Naturally, Pfizer Inc. and its stakeholders are directly interested in the outcome of this request as it affects their operational strategies and cost structures for pharmaceutical production in Michigan. Companies operating in the pharmaceutical industry especially those involved in manufacturing intermediate products should pay attention. This case provides insight into how a major player uses Foreign-Trade Zones for their supply chain and duty management. Businesses that currently operate within Foreign-Trade Zones or are considering establishing operations in an FTZ would also find this notice useful. It illustrates the types of production activities that receive approval and the specific requirements such as the privileged foreign status that can apply. Trade compliance professionals customs brokers and legal experts specializing in international trade law and customs regulations would view this as an important case study. It demonstrates the practical application of FTZ regulations and the impact of Section 232 and Section 301 duties on manufacturing within these zones. Finally, policymakers and economists interested in US trade policy and regional economic development might also examine how such approvals affect local manufacturing and global supply chains.